Prevalence of HPV types in patients with cervical intraepithelial neoplasia of different severity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the prevalence of HPV (human papillomavirus) types in patients with squamous intraepithelial lesions (SIL) of different severity and cervical cancer in comparative perspective. Subjects and methods. This prospective study included 145 women aged 18 to 49 years. The survey consisted of: collecting complaints, anamnesis, gynecological status, conducting extended colposcopy, molecular biological methods (multiplex PCR with detection results in real-time for quantification and typing of HPV 21 types), cytological examination, histological analysis of biopsy material. 5 groups were formed including 145 women: 31 patients (21,3%) - NILM (I group), 30 patients (20,6%) - chronic cervicitis (histologically confirmed) (group II), 37 patients (22,7%) - LSlL (III group), 31 patients (21,3%) - HSIL (IV group ) and 14 patients (9,6%) - cervical cancer (V group). Results. The most significant risk factors for cervical intraepithelial lesions are: early sexual initiation, great number of sexual partners (>4), sexual transmitted infections (STI) history. The most frequent HPV types were 16, 31, 33 and 51 types. We demonstrated that HPV type 16 was significantly more prevalent in the group with HSIL and squamous cervical cancer compared to group II (chronic cervicitis) and group III (LSIL). HPV31 and 33 types are more prevalent in the group with HSIL. According to our results, there is the prevalence of the group A9 HPV in women with LSIL, HSIL and cervical cancer compared to group II (chronic cervicitis). Conclusion. Our results demonstrate the key role of A9 HPV group in the development of premalignant and malignant cervical disease. It should also be noted that in patients with LSIL in addition to A9 HPV group there is a trend to increase the incidence of HPV groups A7, A10, A5.

Full Text

Restricted Access

About the authors

Guranda Merabovna Mzarelua

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: mzareluag@mail.ru
the postgraduate student

Nico Mirzoevna Nazarova

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: grab2@yandex.ru
MD, Ph.D., Senior Researcher

Maria Evgenyevna Nekrasova

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: mashenka_90@mail.ru
the postgraduate student

Elena Gennadyevna Sycheva

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: el.bona@mail.ru
physicial

Olga Vladimirovna Bourmenskaya

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: o_bourmenskaya@oparina4.ru
MD, Researcher of the laboratory of molecular genetics methods

Natalia Leonidovna Starodubtseva

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: n_starodubtseva@oparina4.ru
Candidate of Biological Sciences, Head of the Laboratory of Proteomics and Metabolomics of Human Reproduction

Alexandra Vjacheslavovna Asaturova

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: a_asaturova@oparina4.ru
Senior Researcher, 1st Pathology Department

Gregory Nikolaevich Habas

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: g_khabas@oparina4.ru
Ph.D., Head of the Department of combined and integrated methods of treatment of gynecological diseases

Stanislav Vladislavovich Pavlovich

Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russia

Email: s_pavlovich@oparina4.ru
Ph.D., docent, academic secretary of the Federal State Budget Institution

References

  1. Социально значимые заболевания населения России в 2014 году (статистические материалы). М.: Министерство здравоохранения Российской Федерации, Департамент мониторинга, анализа и стратегического развития здравоохранения ФГБУ “Центральный научно-исследовательский институт организации и информатизации здравоохранения” Минздрава России; 2015. Available at: https://www.rosminzdrav.ru/
  2. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки. Руководство для врачей. 3-е изд. М.: МЕДпресс-информ; 2012.192с.
  3. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 2015; 25(Suppl. 1): 2-23.
  4. Назарова Н.М., Прилепская В.Н., Сычева Е.Г., Зардиашвили М.Д., Бурменская О.В. Новые возможности в диагностике «малых» форм поражений эпителия шейки матки, ассоциированных с папилломавирусной инфекцией. Гинекология. 2015; 17(5): 32-6.
  5. Prilepskaya V.N., Nazarova N.M., Trofimov D.Y., Bestaeva N.V., Bourmenskaya O.V., Kogan E.A., Sulamanidze L.A. Human papillomavirus infection caused by HPV types 52 and 58 and its role in the development of cervical intraepithelial neoplasia. In: Eurogin 2015. HPV Infection and Related Cancers: Translating Research Innovations into Improved Practice. Sevilla, Spain, 4-7 February 2015): 251.
  6. Shakya S., Syversen U., Asvold B.O., Bofin A.M., Aune G., Nordbo S.A. et al. Prevalence of human papillomavirus infection among women in rural Nepal. Acta Obstet. Gynecol. Scand. 2016; 96(1): 29-38.
  7. LiZ.M., Zeng L.Q., Peng X.H., Mao L.Z., Sun X.L., Li Y.H., Luo X.P. Analysis of clinical and pathological characteristics of high- risk HPV-negative carcinoma of the uterine cervix. Zhonghua Fu Chan Ke Za Zhi. 2016; 51(9): 683-7.
  8. Siegler E., Sharir K., Lavie O., Saked-Misan P., Machulki L., Auslender R. et al. The prevalence of HPV types in women with CIN 2-3 or cervical cancer in Haifa District, Israel. Minerva Ginecol. 2016; 16(9):109-18.
  9. Zeng Z., Yang H., Li Z., He X., Griffith C.C., Chen X. et al. Prevalence and geno-type distribution of HPV infection in China: analysis of 51,345 HPV genotyping results from China’s Largest CAP Certified Laboratory. J. Cancer. 2016; 7(9): 1037-43.
  10. Piroozmand A., Mostafavi Zadeh S.M., Madani A., Soleimani R., Nedaeinia R., Niakan M. et al. The association of high risk human papillomaviruses in patients with cervical cancer: an evidence based study on patients with squamous cell dysplasia or carcinoma for evaluation of 23 human papilloma virus genotypes. Jundishapur J. Microbiol. 2016; 9(4): e32728.
  11. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25(Suppl. 3): C1-230.
  12. Wang L., Wang P., Ren Y., Du J., Jiang J., Jia X. et al. Prevalence of High-Risk Human Papillomavirus (HR-HPV) genotypes and multiple infections in cervical abnormalities from Northern Xinjiang, China. PLoS One. 2016; 11(8): e160698.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies